Lantheus Holdings (LNTH) Total Non-Current Liabilities (2014 - 2026)
Lantheus Holdings' (LNTH) quarterly Total Non-Current Liabilities came in at $1.1 billion in Q1 2026, up 24.32% year-on-year from $872.3 million in Q1 2025, and up 5.31% on a QoQ basis from $1.0 billion in Q4 2025.
Lantheus Holdings (LNTH) Total Non-Current Liabilities (2014 - 2026) Analysis & Trends
Lantheus Holdings (LNTH) has 13 years of Total Non-Current Liabilities data on file, last reported at $1.1 billion in Q1 2026.
- On a quarterly basis, Total Non-Current Liabilities rose 24.32% year-over-year to $1.1 billion in Q1 2026; TTM through Mar 2026 was $1.1 billion, a 24.32% increase from a year earlier, with the FY2025 full-year figure at $1.0 billion, up 16.71% from the prior year.
- Total Non-Current Liabilities for Q1 2026 stood at $1.1 billion, up from $1.0 billion in the prior quarter.
- Over the last five years, Total Non-Current Liabilities for LNTH reached as high as $1.2 billion in Q3 2025 and fell as low as $395.8 million in Q1 2022.
- Historically, Total Non-Current Liabilities has averaged $813.2 million across 5 years, with a median of $851.6 million in 2022.
- Across the five-year window, Total Non-Current Liabilities soared 124.98% in 2022 and slipped 6.63% in 2024, its largest moves.
- Year by year, Total Non-Current Liabilities stood at $851.6 million in 2022, then slipped by 4.61% to $812.3 million in 2023, then gained by 8.62% to $882.3 million in 2024, then gained by 16.71% to $1.0 billion in 2025, then increased by 5.31% to $1.1 billion in 2026.
- Per Business Quant data, the three most recent Total Non-Current Liabilities figures were $1.1 billion in Q1 2026, $1.0 billion in Q4 2025, and $1.2 billion in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Non-Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 87.22 Bn | 85.35 Bn | - | 14.92 Bn |
| 2 | Teva Pharmaceutical Industries | 39.60 Bn | 35.87 Bn | 1.97 Bn | 18.28 Bn |
| 3 | Zoetis | 31.46 Bn | 29.52 Bn | 1.62 Bn | 11.64 Bn |
| 4 | Takeda Pharmaceutical | 26.49 Bn | 22.44 Bn | 4.39 Bn | 33.47 Bn |
| 5 | United Therapeutics | 23.03 Bn | 20.88 Bn | 648.10 Mn | 599.10 Mn |
| 6 | Universe Pharmaceuticals | 23.03 Bn | -10.56 Bn | - | - |
| 7 | Viatris | 20.90 Bn | 19.09 Bn | 1.16 Bn | 20.09 Bn |
| 8 | Neurocrine Biosciences | 17.50 Bn | 16.19 Bn | 800.70 Mn | 1.24 Bn |
| 9 | Elanco Animal Health | 12.33 Bn | 11.91 Bn | 785.00 Mn | 6.26 Bn |
| 10 | Lantheus Holdings | 6.72 Bn | 6.22 Bn | 230.92 Mn | 1.08 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 1.08 Bn |
| Dec 31, 2025 | 1.03 Bn |
| Sep 30, 2025 | 1.16 Bn |
| Jun 30, 2025 | 949.16 Mn |
| Mar 31, 2025 | 872.29 Mn |
| Dec 31, 2024 | 882.33 Mn |
| Sep 30, 2024 | 846.69 Mn |
| Jun 30, 2024 | 888.05 Mn |
| Mar 31, 2024 | 822.69 Mn |
| Dec 31, 2023 | 812.34 Mn |
| Sep 30, 2023 | 760.00 Mn |
| Jun 30, 2023 | 782.08 Mn |
| Mar 31, 2023 | 881.13 Mn |
| Dec 31, 2022 | 851.57 Mn |
| Sep 30, 2022 | 411.40 Mn |
| Jun 30, 2022 | 396.88 Mn |
| Mar 31, 2022 | 395.80 Mn |
| Dec 31, 2021 | 378.51 Mn |
| Sep 30, 2021 | 258.83 Mn |
| Jun 30, 2021 | 257.87 Mn |